ArticleBMJ open2014
Recognition and reporting of suspected adverse drug reactions by surveyed healthcare professionals in Uganda: key determinants.
Article in BMJ open, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- An Awareness of Pharmacovigilance Among Healthcare Professionals Due to an Underreporting of Adverse Drug Reactions Issue: A Systematic Review of the Current State, Obstacles, and Strategy.Current drug safety · 2024Pooled it
- Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review Update.Drug safety · 2023Pooled it
- Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.BMC medicine · 2016Pooled it
- Adverse drug reaction reporting with the Med Safety app in Uganda: a cluster-randomised, controlled trial.The Lancet. Global health · 2025Trial
- Knowledge, attitudes and practices of health care professionals towards pharmacovigilance in Georgia.BMC health services research · 2026Article
- Physicians' gender and specialty in relation to adverse drug reaction reporting in Sweden.European journal of clinical pharmacology · 2026Observational
- Pregnant Women and Vaccine Safety in Uganda: Knowledge, Barriers, and Opportunities for Engagement.Vaccines · 2025Article
- Adequacy of Pharmacovigilance Training in the Health Professional Training Institutions in Uganda: Training Gaps and Opportunities for Improvement.Medical science educator · 2025Article
- Healthcare professionals' willingness to utilize a mobile health application for adverse drug reaction reporting in a limited resource setting: An input for digital health, 2023.European journal of obstetrics & gynecology and reproductive biology: X · 2024Article
- Exploring pharmacovigilance practices and knowledge among healthcare professionals: A cross-sectional multicenter study.SAGE open medicine · 2024Article
- Facilitators and Barriers to Uptake of the Med Safety Mobile App for Adverse Drug Reaction Reporting by Health Workers in Uganda: A Qualitative Study.Drug safety · 2023Article
- Perceptions, practices and barriers to reporting of adverse drug reactions among HIV infected patients and their doctors in 3 public sector hospitals of the Ethekwini Metropolitan, Kwa-Zulu Natal: a cross sectional and retrospective analysis.BMC health services research · 2022Article
- Article
- Pharmacovigilance: Awareness and Practice of Nurses and Midwives in Monitoring and Reporting Adverse Drug Reactions in a Selected University Teaching Hospital, Rwanda.Rwanda journal of medicine and health sciences · 2022Article
- Article
- Article
- Adverse drug reaction reporting by community pharmacists in the Greater Accra Region of Ghana, 2016.Ghana medical journal · 2021Article
- Pharmacovigilance of suspected or confirmed therapeutic ineffectiveness of artemisinin-based combination therapy: extent, associated factors, challenges and solutions to reporting.Malaria journal · 2020Article
- Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso.Drug design, development and therapy · 2020Observational
- Educational intervention to improve the knowledge, attitude and practice of healthcare professionals regarding pharmacovigilance in South-South Nigeria.Therapeutic advances in drug safety · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo assess extent and determinants of past-month recognition of suspected adverse drug reactions (ADR) and past-year ADR reporting among healthcare professionals (HCPs) in Uganda.
settingGeographically diverse health facilities (public, private for-profit, private not-for-profit).
participantsOf 2000 questionnaires distributed, 1345 were completed: return rate of 67%. PRIMARY AND SECONDARY OUTCOME MEASURES: Per cent HCPs who suspected ADR in the past month; reported ADR in the past year.
resultsNurses were the majority (59%, 792/1345). Only half the respondents had heard about pharmacovigilance: 39% of nurses (295/763; 95% CI 35% to 42%), 70% otherwise (383/547; 95% CI 66% to 74%). One fifth (268/1289 or 21%; 95% CI 19% to 23%) had suspected an ADR in the previous 4 weeks, 111 of them were nurses; 15% (190/1296) had reported a suspected ADR in the past year, 103 of them were nurses. Past-month ADR suspicion was more likely by non-nurses (OR=1.7, 95% CI 1.16 to 2.40) and with medical research involvement (OR=1.5, 95% CI 1.05 to 2.15) but past-month receipt of patient ADR-complaint predominated (OR=19, 95% CI 14 to 28). Past-year ADR reporting was higher by hospital staff (OR=1.9, 95% CI 1.18 to 3.10), especially in medicine (OR=2.3, 95% CI 1.08 to 4.73); but lower from private for-profit health facilities (OR=0.5, 95% CI 0.28 to 0.77) and by older staff (OR=0.6, 95% CI 0.43 to 0.91); more likely by HCPs who had ever encountered a fatal ADR (OR=2.9, 95% CI 1.94 to 4.25), knew to whom to report (OR=1.7, 95% CI 1.18 to 2.46), or suggested how to improve ADR reporting (OR=1.6, 95% CI 1.04 to 2.49). Two attitudinal factors were important: diffidence and lethargy.
conclusionsOne in five HCPs suspected an ADR in the past-month and one in seven reported ADR in the previous year. Empowering patients could strengthen ADR detection and reporting in Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.